Prof. WANG Shaomeng from University of Michigan Medical School Visits GIBH

Prof. WANG Shaomeng from the University of Michigan Medical School (UMMS) visited GIBH on the afternoon of May 15^th, 2012 and made a presentation entitled MDM2 inhibitors as new anti-cancer therapies.  The seminar was hosted by Dr. DING Ke, the Director of Institute of Chemical Biology at GIBH.

During the seminar, Prof. WANG Shaomeng elaborated on the structure-based drug design of the orally, active small molecule inhibitor, MDM2.  He also discussed the advancement of MI-733 as a clinical candidate for the treatment of human cancers. The inhibitor has been licensed to the third largest pharmaceutical company in the World, Sanofi-Aventis for $40 million dollars and is currently in Phase I clinical trials. Prof. Wang’s lecture aroused profound interest from the audience and an in-depth discussion about drug discovery research in China, ensued after the seminar.

Later Prof. Wang Shaomeng, on the behalf of the UMMS exchanged views with the leaders at GIBH. Both sides agreed to build international joint laboratories focused on stem cell chemical biology as well as new drug development in China.

Dr. Wang received his Ph.D. in Chemistry from Case Western Reserve University in 1992 and did his postdoctoral training in drug design at the National Cancer Institute, NIH between1992-1996. Dr. Wang joined the faculty at the University of Michigan Medical School in 2001, and he was named the Warner-Lambert/Parke-Davis Professor in Medicine in 2007.  He is the Editor-in-Chief for Journal of Medicinal Chemistry, a premier international journal in medicinal chemistry and drug discovery by the American Chemical Society and has published more than 200 papers in peer-reviewed scientific journals.

Prof. WANG Shaomeng from the University of Michigan Medical School (UMMS) visited GIBH on the afternoon of May 15th, 2012 and made a presentation entitled MDM2 inhibitors as new anti-cancer therapies.  The seminar was hosted by Dr. DING Ke, the Director of Institute of Chemical Biology at GIBH.

During the seminar, Prof. WANG Shaomeng elaborated on the structure-based drug design of the orally, active small molecule inhibitor, MDM2.  He also discussed the advancement of MI-733 as a clinical candidate for the treatment of human cancers. The inhibitor has been licensed to the third largest pharmaceutical company in the World, Sanofi-Aventis for $40 million dollars and is currently in Phase I clinical trials. Prof. Wang’s lecture aroused profound interest from the audience and an in-depth discussion about drug discovery research in China, ensued after the seminar.

Later Prof. Wang Shaomeng, on the behalf of the UMMS exchanged views with the leaders at GIBH. Both sides agreed to build international joint laboratories focused on stem cell chemical biology as well as new drug development in China.

Dr. Wang received his Ph.D. in Chemistry from Case Western Reserve University in 1992 and did his postdoctoral training in drug design at the National Cancer Institute, NIH between1992-1996. Dr. Wang joined the faculty at the University of Michigan Medical School in 2001, and he was named the Warner-Lambert/Parke-Davis Professor in Medicine in 2007.  He is the Editor-in-Chief for Journal of Medicinal Chemistry, a premier international journal in medicinal chemistry and drug discovery by the American Chemical Society and has published more than 200 papers in peer-reviewed scientific journals.